VIRIDIAN THERAPEUTICS INC
VRDNNASDAQTrading Snapshot
- Day Range
- $19.67 – $20.17
- 52-Week Range
- $13.18 – $34.29
- Volume
- $2.73B
- Avg Volume
- $2.39B
- Shares Outstanding
- 113.3M
- Next Earnings
- Oct 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $71M
- Last Q Revenue
- $284,000
- P/E Ratio
- -5.8
- P/S Ratio
- 32.9x
- EPS (TTM)
- $-3.59
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +5.9%
Why Investors Own VRDN
- ✓High-growth profile — revenue up -0.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
VIRIDIAN THERAPEUTICS INC
VRDN
StockOtter · stockotter.spaceAbout VIRIDIAN THERAPEUTICS INC
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Viridian Therapeutics: Two Products, One Commercial Buildout
Viridian Therapeutics shifts focus from regulatory risk to launch execution after FDA approval of Lumvoa for thyroid eye disease (TED). VRDN aims to leverage its commercial infrastructure for both Lumvoa and investigatio
Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main
OTTAWA, Ontario, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (OTCQB: VIRMF) reports initial assay results from its 2026 drill program at the Kraken Main Zone in Labrador.
27,472 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Jupiter Topco LLC
Jupiter Topco LLC acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Comm
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare dis
Algert Global LLC Sells 81,762 Shares of Viridian Therapeutics, Inc. $VRDN
Algert Global LLC lowered its position in Viridian Therapeutics, Inc. (NASDAQ: VRDN) by 14.5% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (
Deutsche Bank AG Invests $8.87 Million in Viridian Therapeutics, Inc. $VRDN
Deutsche Bank AG bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 482,875 shares of the c